Structure− function studies of human apolipoprotein AV: a regulator of plasma lipid homeostasis

JA Beckstead, MN Oda, DDO Martin, TM Forte… - Biochemistry, 2003 - ACS Publications
JA Beckstead, MN Oda, DDO Martin, TM Forte, JK Bielicki, T Berger, R Luty, CM Kay…
Biochemistry, 2003ACS Publications
To investigate structure and function relations of a new member of the exchangeable
apolipoprotein family that modulates plasma lipid levels, recombinant human apolipoprotein
(apo) AV was produced in Escherichia coli and isolated by a combination of nickel chelation
affinity chromatography and reversed-phase HPLC. Antibodies directed against apoA-V
were generated and employed in immunoblotting experiments. Anti-apoA-V IgG gave a
strong response against recombinant apoA-V from E. coli and human apoA-V expressed in …
To investigate structure and function relations of a new member of the exchangeable apolipoprotein family that modulates plasma lipid levels, recombinant human apolipoprotein (apo) A-V was produced in Escherichia coli and isolated by a combination of nickel chelation affinity chromatography and reversed-phase HPLC. Antibodies directed against apoA-V were generated and employed in immunoblotting experiments. Anti-apoA-V IgG gave a strong response against recombinant apoA-V from E. coli and human apoA-V expressed in transgenic mice, but did not recognize human apoA-I or apoA-IV. In neutral-pH buffers, at concentrations of >0.1 mg/mL, isolated lipid-free apoA-V is poorly soluble. By contrast, apoA-V is soluble in 50 mM sodium citrate (pH 3.0). Far-UV circular dichroism analysis and spectral deconvolution reveal that apoA-V possesses 32% α-helix, 33% β-sheet, 16% β-turn, and 18% random coil secondary structure conformers. Temperature-induced denaturation studies gave rise to a transition midpoint of 47.1 °C. Upon being cooled to ambient temperature from 85 °C, apoA-V failed to recover all of the negative ellipticity present in unheated apoA-V. ApoA-V interacts with bilayer vesicles of dimyristoylphosphatidylcholine to form discoidal complexes with diameters in the range of 15−20 nm. However, apoA-V was a poor activator of lecithin:cholesterol acyltransferase where the activity was 8.5 ± 1.8% of that of apoA-I. Furthermore, apoA-V failed to support enhanced efflux of cholesterol from cAMP-treated J774 macrophages, although low levels of efflux were obtained from unstimulated cells. Taken together, the results demonstrate recombinant apoA-V possesses unique structural and functional characteristics, in keeping with its proposed role in the modulation of plasma lipid levels.
ACS Publications